Progress in Managing Heart Failure: an in-depth Review of Sacubitril/Valsartan Combination Therapy

Author:

Hiremath Neeraj1,Hiremath Jayasheela S.1,Nyamagoud Sanatkumar B.1,Viswanatha Swamy Agadi Hiremath1

Affiliation:

1. Department of Pharmacy Practice, KLE College of Pharmacy, Hubli, A Constituent Unit of the KLE Academy of Higher Education and Research, Belagavi, Karnataka, India

Abstract

Abstract Heart failure is a severe cardiovascular condition when the heart fails to adequately pump blood or oxygen to support the body’s organs. Sacubitril/valsartan, an emerging angiotensin receptor-neprilysin inhibitor (ARNI) known for its superior efficacy to conventional treatments, has revolutionized the management of heart failure. The United States Food and Drug Administration has approved the drug’s use in treating patients with chronic heart failure with reduced ejection fraction (HFrEF). Clinical trials have demonstrated its effectiveness in reducing hospitalizations and mortality rates associated with heart failure across various patient populations, including those with low ejection fraction. Numerous significant clinical trials have investigated the drug’s safety and efficacy in treating individuals with heart failure and a failing systemic right ventricle. This review delves into the current landscape of cardiovascular medicine, the role of pharmacology, and the safety profile of this medication.

Publisher

Medknow

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3